EMA Recommends Extension of Therapeutic Indications for Ponatinib By Ogkologos - February 27, 2026 107 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR College Basketball Star Plays First Game in Nearly Two Years After... December 1, 2020 Cancer services during COVID-19: 40,000 fewer people starting treatment February 2, 2021 Identification of Actionable Molecular Alterations in NCI-MATCH November 2, 2020 Pembrolizumab May Help Prevent Early-Stage Melanoma from Returning October 13, 2021 Load more HOT NEWS Seven Centres to form new Cancer Research UK network Advancing Cancer Research as a Married Couple: “Your Stories” Podcast Breastfeeding Duration Could Influence Breast Cancer Risk, Study Shows Receiving a Blood Transfusion During Cancer: What to Know and What...
